Holen Sie sich die Stockscreener-App
5.70
2.56%
-0.15
Handel nachbörslich:
5.70
Schlusskurs vom Vortag:
$5.85
Offen:
$5.8
24-Stunden-Volumen:
652.57K
Relative Volume:
0.83
Marktkapitalisierung:
$235.96M
Einnahmen:
$134.48M
Nettoeinkommen (Verlust:
$-38.94M
KGV:
-5.9786
EPS:
-0.9534
Netto-Cashflow:
$-19.34M
1W Leistung:
-22.76%
1M Leistung:
-16.54%
6M Leistung:
-44.28%
1J Leistung:
-56.36%
1-Tages-Spanne:
$5.56
$5.8483
1-Wochen-Bereich:
$5.30
$7.45
52-Wochen-Spanne:
$5.30
$16.74
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
5.70 | 242.17M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
RxSight Earnings Call Balances Growth With Headwinds - TipRanks
William Blair Maintains RxSight(RXST.US) With Hold Rating - Moomoo
Midday Stock Roundup: Willdan Group Up 14% on Q1 Beat - Orange County Business Journal
RxSight (RXST) Loss Widening To US$46.6 Million Tests Bullish Growth Narratives - Sahm
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook - VisionMonday.com
Piper Sandler Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $10 - Moomoo
RxSight, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
RxSight Q1 Earnings Call Highlights - Yahoo Finance
RXST: Q1 revenue fell 18% year-over-year, but LAL volumes stabilized and gross margin improved - TradingView
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips By Investing.com - Investing.com Nigeria
Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips - Investing.com
RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction - ChartMill
RxSight, Inc. (RXST) Tops Q1 EPS by 12c - StreetInsider
RxSight (RXST) Q1 2026 revenue drops 18.5% as net loss nearly doubles - Stock Titan
Eye-lens maker RxSight says sales slowed, but kept 2026 target - Stock Titan
RxSight, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
RxSight (NASDAQ: RXST) posts wider Q1 loss but keeps 2026 sales outlook - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Rxsight Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Behavioral Patterns of RXST and Institutional Flows - Stock Traders Daily
How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets - Yahoo! Finance Canada
Earnings Preview: RxSight to Report Financial Results Post-market on May 06 - Moomoo
RxSight, Inc. to Present at the Bank of America Healthcare Conference - Bluefield Daily Telegraph
Investors can watch RxSight's Bank of America fireside chat May 13 - Stock Titan
Needham Maintains RxSight (RXST) Buy Recommendation - MSN
RxSight (RXST) to Release Earnings on Wednesday - MarketBeat
RxSight (NASDAQ: RXST) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
[ARS] RxSight, Inc. SEC Filing - Stock Titan
(RXST) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6 - The Manila Times
RXST SEC FilingsRxsight, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
RxSight (RXST) COO exercises stock options, now holding over 79,000 shares - Stock Titan
How The RxSight (RXST) Story Is Shifting With New Guidance And Street Price Targets - Yahoo Finance
RxSight (RXST) Stock: Mid-Year Review (Extends Gains) 2026-04-18Volatility Analysis - Cổng thông tin điện tử tỉnh Lào Cai
RxSight, Inc. (RXST) Stock Analysis: Exploring a 34% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Analysts’ Top Healthcare Picks: RxSight (RXST), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RXST: Premium lens adoption grows as utilization deepens and international expansion accelerates - TradingView
RxSight (RXST) Stock: Valuation Analysis (Steady Decline) 2026-04-15Scalping - Cổng thông tin điện tử tỉnh Lào Cai
Volume Summary: Will RxSight Inc benefit from geopolitical trends2026 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Trend Report: Is RxSight Inc forming a double bottom2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
Retail Surge: Can RxSight Inc deliver consistent EPS growthWeekly Trend Summary & Fast Exit Strategy with Risk Control - baoquankhu1.vn
How (RXST) Movements Inform Risk Allocation Models - Stock Traders Daily
RxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Gains Report: What is RxSight Incs valuation compared to sector2026 Intraday Action & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Market Moves: Will RxSight Inc stock hit new highs in YEARQuarterly Earnings Report & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Analysis Recap: Will RxSight Inc benefit from geopolitical trendsJobs Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Investment Recap: Will RxSight Inc benefit from geopolitical trendsSwing Trade & Stepwise Trade Signal Guides - baoquankhu1.vn
RxSight Inc stock: 300,000 Lens Milestone Signals Growth Potential - AD HOC NEWS
RxSight Reaches 300,000 Light Adjustable Lens Implant Milestone - National Today
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):